Philip A. Kalra
A5086644818- Renal and Vascular Pathologies
- Dialysis and Renal Disease Management
- Chronic Kidney Disease and Diabetes
- Iron Metabolism and Disorders
- Erythropoietin and Anemia Treatment
- Aortic aneurysm repair treatments
- Peripheral Artery Disease Management
- Renal Diseases and Glomerulopathies
- Parathyroid Disorders and Treatments
- Hemoglobinopathies and Related Disorders
- Blood Pressure and Hypertension Studies
- Potassium and Related Disorders
- Heart Failure Treatment and Management
- Cardiovascular Function and Risk Factors
- Acute Kidney Injury Research
- Renal Transplantation Outcomes and Treatments
- MRI in cancer diagnosis
- COVID-19 Clinical Research Studies
- Vasculitis and related conditions
- SARS-CoV-2 and COVID-19 Research
- Cerebrovascular and Carotid Artery Diseases
- Liver Disease Diagnosis and Treatment
- Vascular anomalies and interventions
- Diabetes Treatment and Management
- Abdominal vascular conditions and treatments
Manchester Academic Health Science Centre
2013-2025
University of Manchester
2016-2025
Salford Royal Hospital
2016-2025
Salford Royal NHS Foundation Trust
2015-2024
Northern Health and Social Care Trust
2009-2024
University of Salford
1990-2024
National Health Service
2015-2024
Digital Research Alliance of Canada
2009-2024
Delhi State Cancer Institute
2023
Exeter Hospital
2023
Early clinical data from studies of the NVX-CoV2373 vaccine (Novavax), a recombinant nanoparticle against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that contains full-length spike glycoprotein prototype strain plus Matrix-M adjuvant, showed was safe and associated with robust immune response in healthy adult participants. Additional were needed regarding efficacy, immunogenicity, safety this larger population.In phase 3, randomized, observer-blinded, placebo-controlled...
Before the introduction of erythropoiesis-stimulating agents (ESAs) in 1989, repeated transfusions given to patients with end-stage renal disease caused iron overload, and need for supplemental was rare. However, widespread ESAs, it recognized that necessary optimize hemoglobin response allow reduction ESA dose economic reasons recent concerns about safety. Iron supplementation also found be more efficacious via intravenous compared oral administration, use has escalated years. The safety...
Intravenous iron is a standard treatment for patients undergoing hemodialysis, but comparative data regarding clinically effective regimens are limited.In multicenter, open-label trial with blinded end-point evaluation, we randomly assigned adults maintenance hemodialysis to receive either high-dose sucrose, administered intravenously in proactive fashion (400 mg monthly, unless the ferritin concentration was >700 μg per liter or transferrin saturation ≥40%), low-dose reactive (0 400 of <200...
Sacubitril/valsartan reduces the risk of cardiovascular mortality among patients with heart failure reduced ejection fraction, but its effects on kidney function and cardiac biomarkers in people moderate to severe chronic disease are unknown.The UK HARP-III trial (United Kingdom Heart Renal Protection-III), a randomized double-blind trial, included 414 participants an estimated glomerular filtration rate (GFR) 20 60 mL/min/1.73 m2 who were randomly assigned sacubitril/valsartan 97/103 mg...
Abstract Background and Aims What is the relationship between blood tests for iron deficiency, including anaemia, response to intravenous in patients with heart failure? Methods In IRONMAN trial, 1137 failure, ejection fraction ≤ 45%, either serum ferritin &lt; 100 µg/L or transferrin saturation (TSAT) 20% were randomized ferric derisomaltose (FDI) usual care. Relationships investigated baseline anaemia severity, TSAT, changes haemoglobin from 4 months, Minnesota Living Heart Failure...
Higher phosphate is associated with mortality in dialysis patients but few prospective studies assess this nondialysis managed an outpatient nephrology clinic. This longitudinal study examined whether level was death a referred population.Patients (1203) of chronic kidney disease (CKD) the Chronic Renal Insufficiency Standards Implementation Study were assessed. Survival analyses performed for quartiles baseline relative to GFR, 12-month time-averaged phosphate, and according published...
Functional renal magnetic resonance imaging (MRI) has seen a number of recent advances, and techniques are now available that can generate quantitative biomarkers with the potential to improve management kidney disease. Such sensitive changes in blood flow, tissue perfusion, oxygenation microstructure (including inflammation fibrosis), processes important range diseases including chronic However, several challenges remain move these towards clinical adoption, from technical validation...
Background.Many physicians retain reservations regarding the routine prescription of renin–angiotensin blockade (RAB) in patients with atheromatous renovascular disease (ARVD). Conversely, these are most need cardio- and renal protection offered by RAB. This reservation is mostly because fear precipitating acute deterioration. We aimed to study whether RAB can be used safely ARVD it altered their outcome.
Chronic kidney disease (CKD) is a major risk factor for valvular heart (VHD). Mitral annular and aortic valve calcifications are highly prevalent in CKD patients commonly lead to stenosis regurgitation, as well complications including conduction system abnormalities endocarditis. VHD, especially mitral regurgitation stenosis, associated with significantly reduced survival among patients. Knowledge related VHD the general population not always applicable because pathophysiology may be...
We and others have previously described signatures of tolerance in kidney transplantation showing the differential expression B cell–related genes relative expansions cell subsets. However, all these studies, index group—namely, tolerant recipients—were not receiving immunosuppression (IS) treatment, unlike rest comparator groups. aimed to assess confounding effect regimens develop a novel IS-independent signature tolerance. Analyzing gene three independent transplant patient cohorts (232...
There is a need for more observational studies across different clinical settings to better understand the epidemiology of novel COVID-19 infection. Evidence on characteristics infection scarce in secondary care Western populations.We describe all consecutive positive patients (n = 215) admitted acute medical unit at Fairfield General Hospital (secondary setting) between 23 March 2020 and 30 April based outcome discharge (group 1: alive or group 2: deceased). We investigated risk factors...
The optimal intravenous (IV) iron would allow safe correction of deficiency at a single infusion over short time. FERWON-NEPHRO trial evaluated the safety and efficacy isomaltoside 1000/ferric derisomaltose (IIM) in patients with non-dialysis-dependent chronic kidney disease anaemia.In this randomized, open-label multi-centre conducted USA, were randomized 2:1 to dose 1000 mg IIM or sucrose (IS) administered as 200 IV injections up five times within 2-week period. co-primary endpoints...
Experimental and observational studies have raised concerns that giving intravenous (IV) iron to patients, such as individuals receiving maintenance hemodialysis, might increase the risk of infections. The Proactive IV Iron Therapy in Haemodialysis Patients (PIVOTAL) trial randomized 2141 patients undergoing hemodialysis for ESKD a high-dose or low-dose regimen, with primary composite outcome all-cause death, heart attack, stroke, hospitalization failure. Comparison infection rates between...